China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
000999
주식 순위
#2914
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent... China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of medicinal products. Its operations span both the People's Republic of China and international markets, additionally providing various health-related services. The company's extensive product line includes a wide range of over-the-counter (OTC) medications addressing common conditions such as colds, skin issues, gastrointestinal complaints, coughs, and needs in orthopedics and pediatrics. It also provides prescription drugs, with a focus on areas like traditional Chinese medicine, oncology, cardiovascular and cerebrovascular health, digestive system disorders, orthopedics, and pediatrics. Further offerings comprise Chinese medicine injections, specialized formula granules, and anti-infective agents. These products are often marketed under popular brand families, notably 999 family medicine, Sanjiuweitai series, 999 Ganmaoling series, and 999 dermatitis series. Founded in 1999 and headquartered in Shenzhen, PRC, the company initially operated as Sanjiu Pharmaceutical Co., Ltd. before rebranding to its current name in February 2010. It functions as a subsidiary under the umbrella of China Resources (Holdings) Co., Ltd.
주가
$3.74
시가총액
$6.23B
변동 (1일)
-2.11%
변동 (1년)
-8.54%
국가
CN
거래 China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)
카테고리
Healthcare
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)의 수익
Jun 2026 기준 수익 TTM: $714.70M
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $714.70M입니다. 2024년에 회사는 $629.34M의 수익을 올렸으며 이는 2023년의 수익 $530.39M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.의 수익 기록 (2001 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $714.70M | 2.80% |
| 2025 | $695.23M | 10.47% |
| 2024 | $629.34M | 18.65% |
| 2023 | $530.39M | 37.94% |
| 2022 | $384.52M | 21.98% |
| 2020 | $315.25M | -14.08% |
| 2019 | $366.92M | 46.83% |
| 2018 | $249.89M | 7.08% |
| 2017 | $233.36M | 11.49% |
| 2016 | $209.31M | -11.11% |
| 2015 | $235.46M | 15.78% |
| 2014 | $203.36M | -9.34% |
| 2013 | $224.32M | 8.45% |
| 2012 | $206.84M | 37.53% |
| 2011 | $150.40M | -4.00% |
| 2010 | $156.66M | 18.25% |
| 2009 | $132.48M | 39.94% |
| 2008 | $94.67M | 79.81% |
| 2007 | $52.65M | 60.01% |
| 2006 | $32.90M | 52.20% |
| 2005 | $21.62M | -126.33% |
| 2004 | $-82.11M | -349.03% |
| 2003 | $32.97M | 44.24% |
| 2002 | $22.86M | 11.09% |
| 2001 | $20.58M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $3.62B | 406.21% |
DE
|
|
| $3.40B | 376.42% |
DE
|
|
| $1.72B | 141.17% |
JP
|
|
| $930.30M | 30.17% |
CH
|
|
| $1.69B | 136.83% |
IN
|
